Last reviewed 2026-05-15 · How we verify

Bivalent RBD-based ARVAC-CG vaccine

Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno · Phase 2 active Biologic

Bivalent RBD-based ARVAC-CG vaccine is a Vaccine Biologic drug developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno. It is currently in Phase 2 development for COVID-19.

ARVAC-CG vaccine targets the RBD of SARS-CoV-2

ARVAC-CG vaccine targets the RBD of SARS-CoV-2 Used for COVID-19.

At a glance

Generic name	Bivalent RBD-based ARVAC-CG vaccine
Sponsor	Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Drug class	Vaccine
Target	SARS-CoV-2 RBD
Modality	Biologic
Therapeutic area	Vaccines
Phase	Phase 2

Mechanism of action

The Bivalent RBD-based ARVAC-CG vaccine is a vaccine that targets the receptor-binding domain (RBD) of SARS-CoV-2, eliciting a strong immune response against the virus.

Approved indications

COVID-19

Common side effects

No common side effects on file.

Key clinical trials

ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bivalent RBD-based ARVAC-CG vaccine CI brief — competitive landscape report
Bivalent RBD-based ARVAC-CG vaccine updates RSS · CI watch RSS
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno portfolio CI

Frequently asked questions about Bivalent RBD-based ARVAC-CG vaccine

What is Bivalent RBD-based ARVAC-CG vaccine?

Bivalent RBD-based ARVAC-CG vaccine is a Vaccine drug developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno, indicated for COVID-19.

How does Bivalent RBD-based ARVAC-CG vaccine work?

ARVAC-CG vaccine targets the RBD of SARS-CoV-2

What is Bivalent RBD-based ARVAC-CG vaccine used for?

Bivalent RBD-based ARVAC-CG vaccine is indicated for COVID-19.

Who makes Bivalent RBD-based ARVAC-CG vaccine?

Bivalent RBD-based ARVAC-CG vaccine is developed by Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno (see full Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno pipeline at /company/centro-de-educaci-n-medica-e-investigaciones-cl-nicas-norberto-quirno).

What drug class is Bivalent RBD-based ARVAC-CG vaccine in?

Bivalent RBD-based ARVAC-CG vaccine belongs to the Vaccine class. See all Vaccine drugs at /class/vaccine.

What development phase is Bivalent RBD-based ARVAC-CG vaccine in?

Bivalent RBD-based ARVAC-CG vaccine is in Phase 2.

What does Bivalent RBD-based ARVAC-CG vaccine target?

Bivalent RBD-based ARVAC-CG vaccine targets SARS-CoV-2 RBD and is a Vaccine.

Drug class: All Vaccine drugs
Target: All drugs targeting SARS-CoV-2 RBD
Manufacturer: Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno — full pipeline
Therapeutic area: All drugs in Vaccines
Indication: Drugs for COVID-19
Compare: Bivalent RBD-based ARVAC-CG vaccine vs similar drugs
Pricing: Bivalent RBD-based ARVAC-CG vaccine cost, discount & access